CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于 CAR-T 细胞临床前评价的同基因小鼠模型
英文原题：Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells.
查看英文原题
Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞已经彻底改变了血液系统恶性肿瘤的治疗。遗憾的是，这种改善尚未转化为实体瘤领域的进展。目前用于临床前测试的免疫缺陷模型往往高估CAR-T 细胞疗法的疗效，因为它们无法重现实体瘤特有的免疫抑制性肿瘤微环境。由于CAR-T 细胞单药治疗不太可能对许多实体瘤具有治愈性，因此必须研究联合疗法，例如基质重塑剂和免疫调节剂。评估这些联合疗法需要完全免疫健全的小鼠模型，以重现宿主免疫系统与CAR-T 细胞之间的相互作用。本综述将讨论在CAR-T 细胞临床前评估中改进免疫健全小鼠模型的必要性、此类模型的当前使用情况以及未来方向。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of hematological malignancies. Unfortunately, this improvement has yet to be translated into the solid tumor field. Current immunodeficient models used in pre-clinical testing often overestimate the efficacy of CAR T cell therapy as they fail to recapitulate the immunosuppressive tumor microenvironment characteristic of solid tumors.
As CAR T cell monotherapy is unlikely to be curative for many solid tumors, combination therapies must be investigated, for example, stromal remodeling agents and immunomodulators. The evaluation of these combination therapies requires a fully immunocompetent mouse model in order to recapitulate the interaction between the host's immune system and the CAR T cells. This review will discuss the need for improved immunocompetent murine models for the pre-clinical evaluation of CAR T cells, the current use of such models and future directions.
论文信息
- 作者
- Ahmed EN、Cutmore LC、Marshall JF
- 单位
- Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.United Kingdom
- 文献类型
- 综述
- 期刊
- Cancers2024 Sep 18
- 原文标识
- PubMed 39335157 · DOI 10.3390/cancers16183186
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →